Lumida
/MLAB
⌘K
Mesa Laboratories Inc

Mesa Laboratories Inc

MLAB
$120.87USD-0.03%-0.04 today

MARKET CAP

676.4M

P/E (TTM)

186.0x

FWD P/E

DAY RANGE

$120 – $126

52W RANGE

$59
$133

AI Summary

Stalk
StalkMedium

While the long and medium-term trends remain bullish in Stage 2, recent price action has pulled back below the short EMAs and into the 50 SMA support area. Short-term timing is neutral, and execution should be deferred until price reclaims and accepts above the 9/21 EMAs. We will stalk pullbacks into the rising EMAs or the 50 SMA for a favorable entry.

  • Revenue up 1% to $60.1M; operating income jumped 129% to $7.03M.
  • Operating cash flow rose to $14.7M, up $12.8M YoY on stronger collections.
  • SDC segment organic revenue declined 3.6% amid delivery reliability issues.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$133.9M$184.3M$219.1M$216.2M$241.0M
YoY %+13.8%+37.6%+18.8%-1.3%+11.5%
P / Sales9.3x7.4x4.2x2.8x2.7x
EV / Sales8.8x8.8x5.3x4.1x3.7x
Gross Profit, Adj.$87.0M$109.1M$133.7M$133.3M$150.9M
YoY %+33.1%+25.4%+22.6%-0.3%+13.2%
Margin %65.0%59.2%61.0%61.6%62.6%
EV / Gross Profit13.6x14.9x8.7x6.6x5.9x
EBITDA, Adj.$29.6M$29.8M$36.5M$35.3M$42.1M
YoY %+41.5%+0.6%+22.5%-3.3%+19.4%
Margin %22.1%16.1%16.6%16.3%17.5%
EV / EBITDA39.9x54.6x32.0x24.9x21.1x
EBIT$12.4M$4.7M$3.3M$-272.1M$16.3M
YoY %+56.0%-62.0%-29.4%-8295.0%+106.0%
Margin %9.2%2.6%1.5%-125.9%6.8%
EV / EBIT95.4x345.4x351.0x-3.2x54.4x
Net Income$3.3M$1.9M$930,000$-254.2M$-2.0M
YoY %+84.1%-42.9%-50.3%-27438.3%+99.2%
Net Margin2.4%1.0%0.4%-117.6%-0.8%
EPS (GAAP)$0.64$0.35$0.17-$47.20-$0.36
YoY %+56.1%-45.3%-51.4%-27864.7%+99.2%